Decoy Therapeutics Inc. (DCOY)vsRoyalty Pharma Plc (RPRX)
DCOY
Decoy Therapeutics Inc.
$3.58
+1.42%
HEALTHCARE · Cap: $2.16M
RPRX
Royalty Pharma Plc
$58.60
+0.47%
HEALTHCARE · Cap: $33.84B
Smart Verdict
WallStSmart Research — data-driven comparison
RPRX leads profitability with a 32.0% profit margin vs 0.0%. DCOY trades at a lower P/E of 0.0x. RPRX earns a higher WallStSmart Score of 53/100 (C-).
DCOY
Avoid26
out of 100
Grade: F
RPRX
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DCOY.
Margin of Safety
-60.9%
Fair Value
$36.41
Current Price
$58.60
$22.19 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 32 of every $100 in revenue as profit
16.5% revenue growth
Generating 1.4B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 46.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : DCOY
The strongest argument for DCOY centers on P/E Ratio, Price/Book.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Revenue Growth, Free Cash Flow. Profitability is solid with margins at 32.0% and operating margin at 19.8%. Revenue growth of 16.5% demonstrates continued momentum.
Bear Case : DCOY
The primary concerns for DCOY are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
DCOY profiles as a value stock while RPRX is a growth play — different risk/reward profiles.
DCOY carries more volatility with a beta of 0.58 — expect wider price swings.
RPRX is growing revenue faster at 16.5% — sustainability is the question.
RPRX generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (53/100 vs 26/100), backed by strong 32.0% margins and 16.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Decoy Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. The company is headquartered in Cambridge, Massachusetts.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?